Likes Subject
Up $18+ or >13% is my idea of vinmantoo 02/16/23 9:01 PM
SGEN $139.77 +$1.76 a share (+1.275%) MiamiGent 01/26/23 10:32 AM
Re: MiamiGent post# 631252 MiamiGent 01/26/23 10:12 AM
Good morning Larry. MiamiGent 01/26/23 7:02 AM
SGEN Steady climb now on a red day. MiamiGent 01/24/23 12:29 PM
HUGE gains for $SGEN shares down the road Protocola 07/12/22 3:51 PM
Astellas Pharma, Seagen Get CHMP Positive Opinion for Padcev Phosphene 01/04/22 8:48 PM
Seagen and Astellas’ Padcev for Urothelial Cancer Phosphene 08/18/21 8:05 PM
Seagen, RemeGen Ink $2.6B License Agreement for Anti-HER2 Phosphene 08/18/21 8:03 PM
EMA Committee Recommends Approval for Seagen's Tukysa in Phosphene 12/13/20 7:52 AM
BREAKING NEWS: $SGEN 3 Top Growth Stocks to whytestocks 11/14/20 12:30 PM
Seattle Genetics (SGEN) to Release Earnings on 10/29/20 Phosphene 10/22/20 10:38 AM
As a longtime SGEN shareholder, this price rise vinmantoo 10/13/20 1:58 PM
Seattle Genetics shortens name to Seagen, dropping local Phosphene 10/13/20 9:52 AM
Merck & Co to buy $1bn stake in Phosphene 10/07/20 12:00 PM
Seattle Genetics plans manufacturing expansion with cash from Phosphene 09/28/20 12:05 PM
Seattle Genetics and Genmab Present Data from Tisotumab Phosphene 09/21/20 2:22 PM
Astellas, Seattle Genetics' Padcev bladder cancer trial stops Phosphene 09/18/20 11:58 AM
Breaking News: $SGEN Merck Inks Multibillion-Dollar Deal With whytestocks 09/14/20 10:16 PM
NEWS: $SGEN Seattle Genetics and Merck Announce Two whytestocks 09/14/20 10:00 PM
The Baker Brothers have 27% ownership. Phosphene 08/30/20 11:08 PM
Seattle Genetics to Receive Milestone Payment Under ADC Phosphene 08/30/20 10:18 PM
Seattle Genetics Appoints Ted W. Love, M.D., to Phosphene 08/22/20 12:48 PM
Hmmm maybe US deny for now T695 08/19/20 3:57 PM
Seattle Genetics gets FDA approval for breast cancer Phosphene 04/17/20 8:35 PM
How a Seattle Genetics cancer drug could help Phosphene 04/13/20 7:52 AM mellow fellow 01/23/20 5:13 PM
Seattle Genetics Achieves Milestone Following European Commission Approval mellow fellow 01/21/20 5:33 PM
$SGEN bears are running whytestocks 11/12/19 11:25 AM
Seattle Genetics will receive an upfront payment and Phosphene 11/06/19 12:16 PM
News: $SGEN Seattle Genetics Announces Positive Topline Results whytestocks 10/21/19 12:45 PM
News: $SGEN Here's Why Seattle Genetics Stock Jumped whytestocks 09/30/19 2:00 PM
News: $SGEN Initial Results from MOUNTAINEER Trial Show whytestocks 09/29/19 9:10 AM
News: $SGEN Seattle Genetics and Astellas Announce Results whytestocks 09/28/19 8:00 AM
SGEN DAY PennyStock Alert 09/16/19 9:06 AM
“The current standard of care for initial treatment crudeoil24 11/16/18 3:00 PM
SGEN is a great $$$$$ opportunity. crudeoil24 11/16/18 2:52 PM
Also, Seattle pounded the Packers last night! crudeoil24 11/16/18 2:52 PM
Agree! crudeoil24 11/16/18 2:51 PM crudeoil24 11/16/18 2:50 PM
Boom! > FDA approves Adcetris > SGEN crudeoil24 11/16/18 2:31 PM
SGEN is looking to bust $70. I think 46er 06/12/18 3:20 PM
$SGEN OVER BOUGHT. RETRACE TO $20 imo coming BottomBounce 11/29/17 12:44 AM
There's a whole little flock of new collaborations shub 10/11/17 2:25 PM
It sure is an incoherent and dispersed bunch shub 10/03/17 3:39 PM
Thanks for the tips. I'll sure take a cdaniel394 10/03/17 3:20 PM
CD: Took a nibble of AMFE but it shub 10/03/17 3:17 PM
Thanks C Daniel: shub 10/03/17 2:44 PM
Thank you. Just had a friends brother who cdaniel394 10/03/17 2:42 PM
With all their drugs in testing or trials, shub 10/03/17 2:41 PM
Likes Subject

02/16/23 9:01 PM
01/26/23 10:32 AM
01/26/23 10:12 AM
01/26/23 7:02 AM
01/24/23 12:29 PM
07/12/22 3:51 PM
11/14/20 12:30 PM
10/07/20 12:00 PM
08/30/20 11:08 PM
08/19/20 3:57 PM
PennyStock Alert
09/16/19 9:06 AM
11/16/18 2:52 PM
11/16/18 2:52 PM
11/16/18 2:51 PM
11/16/18 2:31 PM
06/12/18 3:20 PM
11/29/17 12:44 AM
10/03/17 3:20 PM
10/03/17 3:17 PM
10/03/17 2:44 PM
10/03/17 2:42 PM

Seattle Genetics (SGEN)

Posts (Today)
Posts (Total)

Seattle Genetics, Inc. operates as a biotechnology company developing monoclonal antibody-based therapies for the treatment of cancer, including lymphoma, multiple myeloma, leukemia, and solid tumors. The company has a worldwide collaboration agreement with Genentech, Inc. to develop and commercialize SGN-40, a humanized monoclonal antibody that is in phase I and phase II clinical development for patients with diffuse large B-cell lymphoma and multiple myeloma. It also has three other proprietary programs in ongoing clinical trials: SGN-33, SGN-35, and SGN-30. The company's SGN-33 is in a phase IIb clinical trial for the patients with acute myeloid leukemia or myelodysplastic syndromes; and SGN-30 and SGN-35 are in phase II clinical trails for the treatment of CD30-positive hematologic malignancies, such as Hodgkin's disease and anaplastic large cell lymphoma. In addition, it developed proprietary antibody-drug conjugate (ADC) technology comprising highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. The company's product candidates also include SGN-70, a humanized anti-CD70 monoclonal antibody with potent effector function and intrinsic cell-killing ability; and SGN-75, which consists of an anti-CD70 monoclonal antibody linked to an auristatin derivative using its proprietary ADC technology. Seattle Genetics has license agreements with Bayer, CuraGen, Progenics, MedImmune, and PDL BioPharma to use its proprietary ADC technology with their monoclonal antibodies; and an ADC co-development agreement with Agensys and Celera Genomics. The company was founded in 1997 and is headquartered in Bothell, Washington

Most Liked Posts
(Last 30 Days)
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Most Liked Posts
(Last 30 Days)
New Post